Formycon Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Stefan Glombitza

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	8.1yrs
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	2.4yrs
Durée moyenne du mandat des membres du conseil d'administration	3.9yrs

Mises à jour récentes de la gestion

Recent updates

PDG

Stefan Glombitza (59 yo)

8.1yrs

Titularisation

Dr. Stefan Glombitza has been Member of Executive Board at Formycon AG since October 1, 2016 and is Chief Executive Officer from July 01, 2022. Dr. Glombitza served as Chief Operating Officer of Formycon...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Stefan Glombitza	CEO & Member of Executive Board	8.1yrs	pas de données	pas de données
Friedrich-Wilhelm Steinweg	Co-Founder	no data	pas de données	pas de données
Nicolas Combe	Co-Founder	no data	pas de données	pas de données
Enno Spillner	CFO & Member of Management Board	1.6yrs	pas de données	pas de données
Andreas Seidl	Chief Scientific Officer & Member of Executive Board	2.3yrs	pas de données	pas de données
Nicola Mikulcik	Chief Business Officer & Member of Executive Board	2.4yrs	pas de données	pas de données
Sabrina Muller	Director of Investor Relations & Corporate Communications	no data	pas de données	pas de données

2.4yrs

Durée moyenne de l'emploi

53.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 0W4N est considérée comme expérimentée (ancienneté moyenne 2.4 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Bernhard Hampl	Member of Advisory Board	10.7yrs	pas de données	pas de données
Gerhard Schaefer	Member of Advisory Board	11yrs	pas de données	pas de données
Colin Bond	Member of the Supervisory Board	less than a year	pas de données	pas de données
Nicholas Haggar	Deputy Chairman of the Supervisory Board	less than a year	pas de données	pas de données
Johannes Buchner	Member of Advisory Board	8.8yrs	pas de données	pas de données
Thomas Siklosi	Member of Advisory Board	6.3yrs	pas de données	pas de données
Klaus Rohrig	Member of Supervisory Board	3.9yrs	pas de données	pas de données
Wolfgang Essler	Chairman of the Supervisory Board	1.3yrs	pas de données	pas de données
Bodo Coldewey	Member of the Supervisory Board	less than a year	pas de données	pas de données

3.9yrs

Durée moyenne de l'emploi

59yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 0W4N sont considérés comme expérimentés (ancienneté moyenne 3.9 ans).

Formycon Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Formycon AG Announces Supervisory Board and Executive Changes

Formycon AG Announces Changes to Its Executive Board

Formycon AG, Annual General Meeting, Sep 27, 2021

Recent updates

Fresenius Kabi and Formycon Receives U.S. FDA Approval for Biosimilar Otulfi (ustekinumab-aauz)

First half 2024 earnings released: €0.58 loss per share (vs €0.11 profit in 1H 2023)

Formycon AG to Report First Half, 2024 Results on Aug 13, 2024

Now 24% undervalued

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 16%

New minor risk - Share price stability

Formycon AG to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings released: EPS: €4.76 (vs €2.62 in FY 2022)

Formycon AG to Report Fiscal Year 2023 Final Results on Apr 25, 2024

New minor risk - Shareholder dilution

Formycon AG has completed a Follow-on Equity Offering in the amount of €82.840247 million.

First half 2023 earnings released: EPS: €0.11 (vs €6.51 in 1H 2022)

Formycon AG to Report First Half, 2023 Results on Aug 30, 2023

Formycon Announces Submission of the Biologics License Application (Bla) for Fyb203, an Aflibercept Biosimilar Candidate to the U.S. Food and Drug Administration (Fda)

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: €2.62 (vs €1.22 loss in FY 2021)

Formycon AG has completed a Follow-on Equity Offering in the amount of €70.07 million.

First half 2022 earnings released: EPS: €6.51 (vs €0.92 loss in 1H 2021)

Formycon AG Publishes Details of A Previously Undisclosed Pipeline Project – Fyb206 Is A Biosimilar Candidate for Keytruda (Pembrolizumab)

Formycon AG, Polpharma Biologics Group BV and Bioeq AG Announce European Commission Approval for FYB201/Ranivisio1 (Ranivisio - Ranibizumab), a Biosimilar to Lucentis2 (News with Additional Features)

Formycon Ag Announces EU-Approval of FYB201/Ranivisio A Biosimilar to Lucentis

Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara in Phase III Study

Formycon Announces FDA Approval of Fyb201/Cimerlitm1 (Ranibizumab-EQRN) as A Biosimilar Interchangeable with Lucentis®2

Formycon AG Announces Supervisory Board and Executive Changes

Formycon's Biosimilar for Lucentis (Ranibizumab), Receives CHMP Recommendation from EMA

Full year 2021 earnings released: €1.22 loss per share (vs €0.54 loss in FY 2020)

Formycon AG Announces Changes to Its Executive Board

Formycon AG Announces Receipt of Market Authorization of from Medicines and Healthcare Products Regulatory Agency

First half 2021 earnings released: €0.92 loss per share (vs €0.14 loss in 1H 2020)

Formycon AG Provides Revenue Guidance for the Year 2021

Formycon AG and Bioeq AG Announce Submits Biologics License Application for FYB201 to U.S. Food and Drug Administration

Formycon AG Provides Sales Guidance for the Fiscal Year 2021

Full year 2020 earnings released

Formycon Receives Approval for Early Action for COVID-19 Drug FYB207 as Part of a Grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy

Formycon Receives Positive Scientific Advice from Paul-Ehrlich-Institute for the COVID-19 Drug FYB207 and Assures GMP Manufacturing Capacities

Formycon AG, Annual General Meeting, Sep 27, 2021

Formycon's Scientific Collaboration Partners Present FYB207 Results At International Keystone Symposium

Formycon AG and Bioeq GmbH Announce Launch of Phase III Study of FYB202, a Biosimilar Candidate for Stelara(R) (Ustekinumab)

Formycon AG and Bioeq AG Announce Biologics License Application Resubmission Strategy for Fyb201 Has Been Adjusted

Formycon AG to Report Q1, 2020 Results on Jun 22, 2020

PDG

Titularisation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen